Stockwinners Market Radar for September 24, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment buys 2K shares of Amazon.com today

19:50 EDT Orgenesis trading halted, news pending

19:50 EDT Freight Technologies Inc trading halted, news pending

18:40 EDT Sony unveils 'Horizon Zero Dawn Remastered,' 'Ghost of Yotei' at State of Play - At a State of Play event, Sony's (SONY) PlayStation unit made a number of announcements about upcoming video game releases, including: new free downloadble content for PS5 exclusive "Astro Bot," out in Fall 2024; a reveal for "The Midnight Walk," an adventure title for PS5 and PSVR2; a reveal for "Hell is Us," a new action game for PS5 developed by Rogue Factor; a new trailer for PSVR2 game "Metro Awakening VR," out November 7, 2024; a reveal for action-RPG "Archeage Chronicles," out for PS5 in 2025; an announcement that Pocketpair's "Palworld" will be coming to PS5 on Tuesday after previously being available only on PC and Xbox Series X/S (MSFT); announcement that the "Lunar Remastered Collection" is coming to PlayStation consoles in Spring 2025; announcement that former iOS-exclusive role-playing game "Fantasian: Neo Dimension" will be coming to PS5 on December 5; a new trailer for Electronic Arts' (EA) multiplatform role-playing game "Dragon Age: The Veilguard," out October 31, 2024; a new trailer for "Alan Wake 2: The Lake House," a downloadble expansion to "Alan Wake 2"; an announcement that "Hitman: World off Association" is coming to PSVR2 later this year; an announcement that Koei Tecmo's "Dynasty Warriors: Origins" will release January 17, 2025; a new trailer for Capcom's (CCOEY) "Monster Hunter Wilds," out February 28, 2025; an update trailer for Sony-published "LEGO Horizon Adventures," out November 14, 2024; a confirmation that "Horizon Zero Dawn Remastered" is coming to PS5 and PC, out October 31, 2024; and a reveal trailer for PS5 exclusive action game "Ghost of Yotei," out in 2025.

17:49 EDT Salesforce to acquire data management provider Zoomin, no terms - Salesforce has signed a definitive agreement to acquire Zoomin, a leading data management provider for unstructured data. Salesforce Data Cloud, with Zoomin's capabilities, will accelerate the unlocking of unstructured data to power AI agents, making them more personalized and context-aware in every customer interaction. With this, Salesforce's Agentforce will gain new levels of intelligence, enabling customers to build AI that provides real-time, data-informed responses and actions tailored to individual customer needs. The acquisition is expected to close in the fourth quarter of Salesforce's fiscal year 2025, subject to customary closing conditions. "Proprietary unstructured data is powerful fuel our customers can use for AI agents and customer experiences, and Zoomin's proven expertise and technology will accelerate Data Cloud's innovation and enable our customers to get better value from Agentforce," said Rahul Auradkar, EVP & GM, Unified Data Services & Einstein. "This proposed transaction underscores our continued commitment to enable our customers to harness the value all of their data into the #1 AI CRM through Data Cloud, as well as to activate relevant, contextual information to ground unique AI experiences with enterprise-leading trust controls."...Zoomin has been a Salesforce AppExchange partner since 2018 and a Salesforce Ventures portfolio company since 2019. Through the existing partnerships between Salesforce and Zoomin, hundreds of Salesforce customers are already using Zoomin's unified knowledge product to deliver intuitive experiences to their customers, partners, and employees. This transaction does not result in any change to Salesforce's current financial guidance previously provided in August 2024 and we will not be disclosing any further financial details. Reference Link

17:33 EDT HII awarded $3.67B Navy contract modification - HII was awarded a $3.67B fixed-price incentive modification to a previously awarded contract to definitize the advance procurement of long lead time material procurement and procure the detail design and construction and special studies in support of one amphibious assault ship replacement America class Flight 1 ship. This contract modification includes options which, if exercised, would bring the cumulative value of this contract to $3.89B. Work is expected to be completed by September 2033. If all options are exercised, work will continue through March 2035. FY23 shipbuilding and conversion funds in the amount of $115M and FY22 shipbuilding and conversion funds in the amount of $203,039, will be obligated at time of award and will not expire at the end of the current fiscal year. Naval Sea Systems Command is the contracting activity.

17:31 EDT HII awarded $5.8B Navy contract - HII was awarded a $5.8B fixed-price incentive contract for detail, design, and construction of three amphibious transport dock ships Flight II. Work is expected to be completed by September 2035. FY24 shipbuilding and conversion funds in the amount of $449M; and FY21 shipbuilding and conversion funds in the amount of $1M, will be obligated at time of award and will not expire at the end of the current fiscal year. This contract was not competitively procured in accordance with 10 U.S. Code 2304(c)(1) and 10 U.S. Code 3204(a)(1). Naval Sea Systems Command is the contracting activity.

17:23 EDT Planet Labs releases Forest Carbon Monitoring product at 3-meter resolution - Planet Labs PBC released its Forest Carbon Monitoring product, consisting of quarterly, 3-meter resolution measurements of forests globally. This new product offers partners and customers an unprecedented dataset to support voluntary carbon markets, regulatory compliance, and deforestation mitigation. "Tackling climate change requires significant investment in carbon projects. BeZero Carbon's 80-strong science team interrogates these projects using the most timely and complete data possible, so that investments can be made with a clear view of credit quality," said Dr. Phil Platts, VP of Geospatial and Earth Observation at BeZero Carbon. "Planet's Forest Carbon Monitoring product is the first and only dataset delivering high cadence, global forest carbon estimates at 3-meter resolution. That level of granularity can make a big difference for monitoring forest intactness, management practices, or scattered trees on farmland." Platts continued, "We rate hundreds of projects, of all kinds, all over the world. Doing so requires an enormous range of data, which we evaluate and combine project by project. Having Planet data in the mix is incredibly helpful, and we are using it to detect individual trees, right up to jurisdictional accounting."

17:19 EDT Bath & Body Works to replace Movado in S&P 600 at open on 10/1

17:18 EDT Amentum to replace Bath & Body Works in S&P 500 at open on 9/30 - Amentum Holdings (AMTM) will be added to the S&P 500 effective prior to the open of trading on Monday, September 30, replacing Bath & Body Works (BBWI), which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Tuesday, October 1.

17:02 EDT Lifeward to sell AlterG family of products through its German sales organization - Lifeward announced that it will begin selling the AlterG family of products through its German sales organization, effective immediately. The announcement was made at today's REHACARE 2024 conference in Dusseldorf, Germany, where the new AlterG NEO will be available for live demonstrations and purchase. The move adds the AlterG product line to the ReWalk Personal Exoskeleton in Lifeward's German sales portfolio. The Company expects several financial benefits from selling directly, including greater revenue due to a more focused sales effort and higher margins with little incremental investment by utilizing its existing sales and support infrastructure in Germany. AlterG products have been available to customers in Germany since 2013 through a distribution arrangement with PHYSIOMED GROUP, formerly proxomed Medizintechnik. Under this existing contract, PHYSIOMED GROUP will continue to provide service and support to its existing base of nearly 500 customers in Germany and will continue to distribute AlterG units in parallel with the Lifeward team.

16:56 EDT Fulcrum Therapeutics to reduce workforce from 80 to 51 full-time employees - On September 24, Fulcrum announced the approval by its board of directors of a plan to reprioritize research and development activities to focus on advancing pociredir for the treatment of sickle cell disease, novel therapeutic agents for the treatment of Diamond-Blackfan anemia, and its early discovery programs. The plan will reduce the Company's workforce from 80 to 51 full-time employees, including a reduction of positions across both research and development and general and administrative. Fulcrum expects to incur one-time costs of approximately $2M in connection with this workforce reduction, primarily related to cash payments for severance. The Company communicated the workforce reduction on September 24 and expects the majority of the costs associated with the reduction to be incurred during the third quarter ending September 30 . The Company expects that the implementation of the workforce reduction will be substantially complete by the end of the third quarter of 2024. The workforce reduction is expected to result in annual operating expense savings of approximately $10M beginning in the first quarter of 2025. The charges Fulcrum expects to incur in connection with this reduction in force are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. Fulcrum may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions. This information is from a company 8K filing. Reference Link

16:53 EDT Stitch Fix reports FY24 gross margin up 190bps from FY23 at 44.3% - This is the company's "highest annual gross margin since FY21".

16:48 EDT Norfolk Southern names Jason Zampi as CFO, Jason Morris as Chief Legal Officer - Norfolk Southern has named Jason Zampi as Executive Vice President, CFO and Treasurer, and has named Jason Morris as Senior Vice President, Chief Legal Officer and Corporate Secretary, effective immediately. As CFO and Treasurer, Zampi will oversee the company's financial departments as well as Strategic Planning. He has more than 28 years of finance and accounting expertise, including 13 years with Norfolk Southern where he has advanced through key roles in forecasting, budgeting, and corporate accounting. Prior to joining Norfolk Southern, Zampi was a senior manager with KPMG LLP. As CLO and Corporate Secretary, Morris will oversee the company's legal, government relations, corporate secretary, and compliance departments. He joined Norfolk Southern's legal department in 2010 and took on roles of increasing responsibility there before also serving in the Operations and Transformation divisions.

16:47 EDT Farmers & Merchants raises dividend 0.125c to 22.125c - The Board of Directors of Farmers & Merchants Bancorp, the holding company of F&M Bank, announced that it has approved the Company's quarterly cash dividend of 22.125c per share. The Q3 dividend is payable on October 20 to shareholders of record as of October 4. The 22.125c per share cash dividend reflects a 0.125c per share increase in the quarterly dividend, representing the 30th consecutive annual increase in the Company's regular dividend payment.

16:36 EDT Envestnet shareholders approve acquisition by Bain Capital - Envestnet announced that, at a special meeting, the Company's stockholders approved the pending acquisition of the Company by affiliates of vehicles managed or advised by Bain Capital. Based on a preliminary tally of voting results, approximately 99.33% of the votes represented at the Special Meeting were in favor of the Merger.

16:33 EDT Commvault to acquire Clumio, terms not disclosed - Commvault announced it will acquire Clumio, a technology company in data protection for critical cloud data in AWS. This transaction enables Commvault to leverage Clumio's AWS offerings to provide cyber resilience to next generation applications built on AWS. Clumio serves a wide range of customers including Atlassian, Cox Automotive, Duolingo, and LexisNexis. The asset acquisition is expected to close in early October 2024, and be immediately accretive to ARR and revenue, and accretive to free cash flow within the next three quarters. The purchase price is not material to Commvault and will be funded with cash on hand. Commvault reiterates the fiscal second quarter 2025 earnings guidance previously announced on July 30, 2024. .

16:32 EDT Air Lease delivers first of six new Airbus A220-300 to TAAG Angola Airlines - Air Lease "announced the delivery of one new Airbus A220-300 to TAAG Angola Airlines, the national carrier of Angola. This is the first A220 aircraft to deliver on long-term lease to TAAG and is the first of six new A220-300s confirmed to deliver to the airline from ALC's orderbook with Airbus."

16:29 EDT Kairos Pharma collaborates with PreCheck on ENV105 companion biomarkers - Kairos Pharma announced a collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of companion biomarkers for Kairos Pharma's cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma's Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105. Kairos Pharma and PreCheck Health Services will utilize advanced molecular diagnostics to corroborate and further develop biomarkers previously identified in a Phase 2 clinical trial. These biomarkers are designed to predict patient responses to ENV105 prior to treatment, offering a more personalized approach to cancer care. Under the agreement, PreCheck will analyze biopsy tissues and circulating tumor cells from patients enrolled in Kairos Pharma's ongoing clinical trials, including a Phase 2 randomized, multi-institutional trial in prostate cancer and a Phase 1 trial in lung cancer. The goal is to confirm the predictive capabilities of these biomarkers and to discover new biomarkers that can identify suitable candidates for the novel therapy. The collaboration will rely on PreCheck's proprietary SolidTumorCheck+ platform, which allows for gene expression profiling of tumor biopsies. This technology will be employed to examine samples from patients with both lung and prostate cancer. Furthermore, the analysis of circulating tumor cells aims to offer non-invasive insights, potentially leading to the development of liquid biopsy tests for future patient screening and therapy monitoring. The biomarkers will be tested in two key clinical trials: NCT05401110: A Phase 1 trial targeting patients with EGFR-driven lung cancer who have developed resistance to osimertinib. Pre-treatment biopsies will undergo somatic gene expression profiling using the SolidTumorCheck+ platform to identify biomarkers that can predict a favorable response to ENV105. NCT05534646: A phase 2 trial for patients with castrate-resistant prostate cancer who have shown resistance to multiple androgen receptor signaling inhibitors. Here, the focus will be on the somatic profiling of circulating tumor cells and tumor biopsies to confirm previously identified biomarkers and identify any new ones tied to ENV105's efficacy. Both trials aim to integrate biomarker analysis into treatment plans, ensuring that patients most likely to benefit from ENV105 are accurately identified.

16:22 EDT Progress Software reports Q3 EPS $1.26, consensus $1.13 - Reports Q3 revenue $178.69M, consensus $175.94M. Yogesh Gupta, CEO of Progress said: "This is a very exciting time for Progress. Our Q3 results were ahead of our guidance, and I am extremely pleased with our execution during the quarter. What's more exciting is our proposed acquisition of ShareFile, which we announced two weeks ago. We expect the deal to close before the end of our fiscal year, and we are eager to begin the work of integrating ShareFile's people and products into the Progress team."

16:18 EDT American Healthcare acquires remaining 24% membership interest in Trilogy - American Healthcare REIT has now exercised its purchase option to acquire the remaining 24% minority membership interest in Trilogy REIT Holdings, that had been held by the Company's joint venture partner, an affiliate of NorthStar Healthcare Income. Upon the closing of the acquisition, the Company became the sole owner of Trilogy Holdings and the Company's Integrated Senior Health Campuses, or ISHC. Details of the transactions are as follows: On September 20, the Company acquired the 24% minority membership interest for a total all-cash purchase price of approximately $258M, which includes the pre-negotiated "base" purchase price of $247M and the approximate $11M pro-rata distribution owed to the Company's joint venture partner through the closing date of the acquisition. The Company funded the acquisition using net proceeds from its equity offering that also closed on September 20, and the Company used the remaining net proceeds from the equity offering to repay approximately $194.0M of debt outstanding on its lines of credit. Based on the Company's results for the three months ended June 30, and assuming the Company had closed the acquisition as of the first day of such period, the Company's ISHC segment would have comprised approximately 55.3% of the Company's total portfolio cash net operating income for such period. "We are excited to have completed the acquisition of our joint venture partner's 24% minority membership interest in Trilogy Holdings in an accretive and leverage neutral manner. Additionally, we paid down existing outstanding indebtedness on our lines of credit with the remaining net proceeds from our recent common stock offering, which we believe will result in further accretion and borrowing capacity," said Danny Prosky, American Healthcare REIT's President and CEO.

16:17 EDT Primerica names Robert Peterman Jr. as successor to COO - Primerica announced the appointment of Robert H. Peterman Jr. to the role of Executive Vice President and Chief Operating Officer, reporting to the company's Chief Executive Officer, Glenn Williams, beginning on October 1, 2024. Gregory C. Pitts, the Company's current Executive Vice President and Chief Operating Officer, informed the Company of his intention to retire after forty years of service on or about April 1, 2025, and he will relinquish the Chief Operating Officer title effective October 1, 2024. "For over four decades, Greg Pitts has provided high-impact leadership to Primerica. No task has been too difficult, and no responsibility has been too large for him to engage and lead. Greg is a role model to others and one of his greatest accomplishments has been developing a team of leaders who will continue his standard of excellence years into the future," said Glenn Williams, Primerica CEO.

16:15 EDT KB Home raises FY24 housing revenue to $6.85B-$6.95B from $6.7B-$6.9B - Affirms FY24 average selling price midpoint of about $490K. Narrows FY24 Homebuilding operating income as a percentage of revenues outlook to 11.1%-11.2% frp, 11.0% to 11.4%.

16:13 EDT Alpine Income Property says Q3 total investment activity $55.3M at 9.2% yield - Alpine Income Property Trust announced updated third quarter and year-to-date 2024 investment and disposition activities. In September 2024, the Company purchased and amended a first mortgage construction loan secured by a Publix-anchored shopping center and three outparcels located in Charlotte, NC. The current loan commitment is for $17.8M, of which $10M was funded at closing at an initial interest rate of 10.25%. The rate of the loan increases by 0.25% every 30 days to a maximum rate of 11.00%. However, upon certain leasing criteria being met, the rate will be lowered to 9.50%.The Company's third quarter total investment activity, including acquisitions and structured investments activity, now totals $55.3M at a weighted average initial investment yield of 9.2%.The Company's year-to-date total investment activity, including acquisitions and structured investment activity, now totals $84.2M at a weighted average initial investment yield of 9.4%. Since the last announced update, the Company sold an additional five net leased retail properties, leased to Hobby Lobby, Long John Silvers, Chick-fil-A, Tractor Supply and LA Fitness, for a total disposition volume of $28.5 million."We are pleased at our ability to continue investing into better located, higher yielding and higher quality properties utilizing the proceeds from lower yielding dispositions" said John P. Albright, President and Chief Executive Officer of Alpine Income Property Trust. "Our accretive recycling efforts will provide further growth in our earnings and portfolio diversification."

16:09 EDT Jeffs' Brands: Fort's growth accelerates in Europe following launch of sales - Jeffs' Brands announced the successful growth of its subsidiary Fort Product across Europe following its recent launch of commercialization of its products in multiple territories. Fort's strong performance and positive reviews in the UK have proven instrumental in driving demand for Fort's pest control solutions in additional European markets. "We are thrilled to see the strong momentum behind Fort's sales growth in Europe," said Viki Hakmon, Jeffs' Brands' CEO. "Our data-driven approach has allowed us to identify key market opportunities, and we believe that Fort's superior product quality and expanding reach will continue to unlock new avenues for growth across the region." This increase in sale volumes aligns with Jeffs' Brands' strategy of expanding Fort's product offerings and footprint in Europe through Amazon's advanced marketplace tools and customer insights. The Company remains focused on further geographical expansion and is committed to increasing Fort's market share across additional European countries.

16:07 EDT Lifeway Foods confirms $25.00 per share buyout proposal from Danone - Lifeway Foods (LWAY) confirmed that it has received an unsolicited, non-binding proposal from Danone North America PBC (DANOY) to acquire all outstanding shares of common stock of Lifeway it does not already own for $25.00 per share in cash. According to the Schedule 13D amendment filed yesterday with the U.S. Securities and Exchange Commission disclosing the proposal, Danone beneficially owns approximately 23.4% of Lifeway's outstanding common stock. Consistent with its fiduciary duties, Lifeway's board of directors, in consultation with its independent outside advisors, will carefully review and evaluate the proposal to determine the course of action that it believes is in the best interests of the Company and its stakeholders.

16:03 EDT Amgen announces approval of TEPEZZA to treat CAS or TED in Japan - Amgen announced TEPEZZA has been approved for the treatment of active or high clinical activity score, or CAS, Thyroid Eye Disease, or TED, by Japan's Ministry of Health, Labour and Welfare, or MHLW. TED is a serious, progressive and potentially vision-threatening rare autoimmune disease that can cause proptosis, or eye bulging, diplopia, or double vision, eye pain, redness and swelling. There are approximately 25,000 - 35,000 people living with TED in Japan, inclusive of both active and chronic TED. TEPEZZA is now the first and only medicine approved in Japan to treat active TED. A separate trial to study the efficacy of TEPEZZA in chronic TED patients in Japan is currently ongoing. TEPEZZA received orphan drug designation in Japan, which provided a nine-month regulatory review period compared to the standard 12-month review. The approval was based on the positive results of OPTIC-J, a Phase 3 randomized, double-masked, placebo-controlled, parallel-group, multicenter study evaluating the efficacy, tolerability and safety of TEPEZZA in the treatment of patients with active TED in Japan. The primary endpoint in the trial was met, as 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis compared with placebo at week 24.

15:18 EDT ICL openes food specialty plant in China, for novel foods and palates - ICL announced it has opened a new food specialty plant in China, which was designed to help customers easily partner with ICL to create novel and innovative food offerings tailored to Chinese consumers' palates. The facility will manufacture specialty food solutions in the meat, poultry and seafood segments, such as texturants and marinades, among other offerings, and was built in the thriving Zhangjiagang Free Trade Zone, which is located in the heart of the Greater Shanghai area...."We were delighted to join ICL Group at the opening of their new food specialty plant and look forward to continuing to partner with them - a relationship that began more than 20 years ago - as they further expand in China," said San Ping Zhang, SVP at Yurun Group, one of the largest meat producers in China. "Their experience in the premium food ingredients market makes them the obvious choice, as we look to further strengthen the market position and image of our brands as healthy, high-quality, delicious and high-end."

15:00 EDT Nano Nuclear Energy awarded Department of Energy GAIN Nuclear Energy voucher - The Gateway for Accelerated Innovation in Nuclear, or GAIN, announced that four companies will be provided a GAIN Nuclear Energy Voucher to accelerate the innovation and application of advanced nuclear technologies. NE vouchers provide advanced nuclear technology innovators with access to the extensive nuclear research capabilities and expertise available across the U.S. Department of Energy national laboratory complex. This is the fourth award for FY 2024. The businesses selected to receive a GAIN nuclear energy voucher for Round 4 FY 2024 include Nano Nuclear Energy with the awarded proposal "Independent Assessment of a Novel Heat Exchanger Concept for Open-Air Brayton Cycle. Idaho National Laboratory is the partner facility. Advanced Nuclear Advisors, Antares Nuclear, and Sigma-Aldrich Inc. DBA MilliporeSigma are the other recipients of NE vouchers. Reference Link

14:32 EDT DOJ files antitrust suit against Visa over debit network practices - In a filing made in the U.S. Southern District Court of New York, the Department of Justice Antitrust Division alleged Visa has "monopolized debit transactions; penalized industry participants that seek to use alternative debit networks; and coopted innovators, technology companies, and financial institutions to forestall or snuff out threats to Visa's debit network dominance." In the lawsuit, the DOJ requests that the Court adjudge and decree that Visa has acted unlawfully to monopolize, or, in the alternative, attempt to monopolize, the market for general purpose card-not-present debit network services in the United States as well as the market for general purpose debit network services in the United States and "enter such relief as needed to cure the anticompetitive harm from all of Visa's unlawful actions" as well as enjoin Visa from "continuing to engage in the anticompetitive practices described herein and from engaging in any other practices with the same purpose or effect as the challenged practices." Reference Link

14:21 EDT Microsoft expands Global Engineering Development Ccenter footprint to UAE - Microsoft announced it is expanding its Global Engineering Development Center footprint to the UAE. A new development center, which will be established in Abu Dhabi, is Microsoft's first engineering center to be launched in the Arab world, joining the company's global portfolio of development centers across key strategic locations around the world. Microsoft's Engineering Development Center in Abu Dhabi will be part of a global ecosystem of centers dedicated to the creation of AI innovations, cloud technologies and advanced cybersecurity solutions. The engineering teams at the center will create cutting-edge solutions that will be part of Microsoft solutions globally. Satya Nadella, Chairman and CEO, Microsoft, said, "We are committed to ensuring transformative technologies, like AI, benefit everyone broadly and create local opportunity. Our Engineering Development Center in Abu Dhabi will bring new talent to the region and help power innovation that will drive economic growth and job creation for both the UAE and the world."

14:06 EDT Invitation Homes confirms $48M settlement with FTC - Invitation Homes confirmed that it reached agreement with the Federal Trade Commission resolving the FTC's civil investigation into certain company business practices. As part of the resolution, Invitation Homes will pay the FTC $48M in monetary relief, with no civil penalties. The agreement contains no admission of wrongdoing by Invitation Homes. "Invitation Homes believes that its disclosures and practices are industry leading, both among its professional peers as well as the millions of smaller owners of single-family homes for lease. Today's agreement brings the FTC's three-year investigation to a close and puts this matter behind the Company, which will, as always, move forward with its continuous efforts to better serve its customers and enhance its practices. Invitation Homes remains committed to providing a high-quality living experience for individuals and families who want flexibility and choice in housing and to transparency with all stakeholders," the company said in a statement.

13:17 EDT PG&E awarded $34.5M in federal grants for 19 hydroelectric projects - PG&E has been awarded $34.5M in grant awards from the U.S. Department of Energy Grid Deployment Office to support 19 hydroelectric projects across its system. The grant awards are part of the DOE's Maintaining and Enhancing Hydroelectricity Incentive program, and will fund work that provides grid resiliency, improves dam safety, and reduces environmental impacts associated with ongoing operations.

12:38 EDT Elliott intends to call Southwest special meeting in coming weeks - Elliott Investment Management, which manages funds that together have an investment representing an approximately 11% economic interest in Southwest Airlines, sent a second open letter to the company's shareholders. In the letter, Elliott Partner John Pike and Portfolio Manager Bobby Xu "wrote that although Elliott's goal has been to collaborate with Southwest to restore accountability and best-in-class financial performance, Southwest has chosen a go-it-alone path, featuring a chaotic series of defensive actions, with the goal of obstructing a leadership change that is urgently needed. The letter made clear that Elliott intends to formally call a special meeting in the coming weeks - possibly as soon as next week. The letter also alerted shareholders to certain defensive actions that Southwest's leaders are taking and urged them to take action to ensure they would be able to vote their shares."

12:00 EDT Orion Group falls -8.4% - Orion Group is down -8.4%, or -51c to $5.51.

12:00 EDT MultiPlan falls -24.2% - MultiPlan is down -24.2%, or -$2.17 to $6.78.

12:00 EDT AMTD Digital rises 17.1% - AMTD Digital is up 17.1%, or 50c to $3.42.

11:50 EDT Pfizer, BioNTech updated COVID vaccine authorized in Canada - Pfizer Canada (PFE) and BioNTech (BNTX) announced that Health Canada has authorized the KP.2 variant adapted Comirnaty COVID-19 vaccine for ages six months and older. The updated Comirnaty vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages, the company said in a statement. The adapted COVID-19 vaccine will be available in Canada as a single dose for individuals five years of age and older, regardless of prior COVID-19 vaccination history. For children six months through four years of age, Comirnaty is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course.

11:02 EDT Richardson Electronics enters global distribution agreement with Quantic MWD - Richardson Electronics announced a global distribution agreement with Quantic MWD. This new technology partnership network will enhance the accessibility of Quantic MWD's products to a broad range of customers. Quantic's solutions maximize stability and minimize noise under extreme environmental conditions, whether in space, defense, or industrial applications.

10:50 EDT EHang announces EH216-S eVTOL completes first flight in Brazil - EHang Holdings announced a major milestone with the completion of the first flight of its EH216-S pilotless eVTOL in Brazil. EHang's first trial flight in Brazil took place in Quadra, located in the Sao Paulo region, in partnership with its local operator, Gohobby Future Technologies. This achievement holds significant importance for the future development of UAM solutions in Brazil, a country known as the birthplace of Latin American aviation, home of one of the world's leading aeronautical industries, and one of the world's largest eVTOL markets. As for now, EHang and its local partners have carried out over 50,000 safe flights in 17 countries across Asia, Europe, North America, and Latin America.

10:01 EDT BAE Systems awarded $19M contract from U.S. Navy - BAE Systems has received a $19M contract from the U.S. Navy to design and implement UPX-24 target data processor capabilities into a single digital interrogator Identification Friend or Foe solution. The upgraded IFF digital interrogator will optimize data collection and processing to provide time-critical insights and enhance decision making for the maritime fleet. Work on the advanced IFF digital interrogator target data processor solution will be performed at BAE Systems' state-of-the-art facility in Greenlawn, New York.

10:00 EDT Orion Group falls -6.1% - Orion Group is down -6.1%, or -37c to $5.65.

10:00 EDT Nuscale Power rises 8.8% - Nuscale Power is up 8.8%, or 96c to $11.85.

10:00 EDT Tencent Music rises 12.3% - Tencent Music is up 12.3%, or $1.25 to $11.43.

09:48 EDT Full Truck Alliance rises 11.0% - Full Truck Alliance is up 11.0%, or 84c to $8.48.

09:47 EDT Triumph Group falls -4.4% - Triumph Group is down -4.4%, or -60c to $12.95.

09:47 EDT Hawaiian Electric falls -12.2% - Hawaiian Electric is down -12.2%, or -$1.32 to $9.57.

09:33 EDT Verizon Business announces contract with South Carolina Army National Guard - Verizon Business today announced a new contract with the South Carolina Army National Guard, becoming the primary wireless communications provider of the state-based military components. The deal encompasses connectivity for more than 1,000 devices ranging from 5G Ultra Wideband and 4G LTE smartphones to data devices like jet packs. The communications capabilities provided by these devices will play a key factor in the SCARNG's ability to achieve its mission across the state of South Carolina. The SCARNG will also have access to the Verizon Frontline Crisis Response Team, a specialized group composed primarily of former first responders and military personnel, dedicated to supporting public safety and government agencies during emergencies at no cost to the supported agencies.

09:25 EDT China Medical System announces NDA acceptance for ruxolitinib cream in China - China Medical System announced that on September 24, 2024, the New Drug Application for vitiligo indication of ruxolitinib phosphate cream has been accepted by the National Medical Products Administration of China. This is another substantial milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo, and it is also a key step in benefiting over ten million of patients with vitiligo in China. Ruxolitinib cream achieved positive results in Chinese Real-World Study. The primary efficacy endpoint was the proportion of patients in the treatment group who achieved F-VASI 75 response at week 24, which was 49.5%, significantly higher than the target value of 14.1%. The study met its primary endpoint, demonstrating that ruxolitinib cream is effective in treating patients with nonsegmental vitiligo, reducing the area of the lesions, and repigmenting the skin. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Adverse events mostly had severity levels of grade 1 or 2. No adverse event leading to discontinuation or withdrawal, and no serious adverse event related to the study drug occurred. While advancing the process of NDA for the Product, the Group is conducting the transfer of ruxolitinib cream from overseas production to domestic production, which is being orderly promoted by the Contract Development Manufacturing Outsourcing Organization, and the lab-scale and pilot trial studies have been completed and under scale-up production. The Group strives to complete the localization study as soon as possible, register in Mainland China and obtain marketing approval, so as to enable the Chinese patients with vitiligo to use the innovative product.

09:20 EDT Hudson comments on EPA's issuance of final refrigerant management rule - Hudson Technologies commented on the Final Rule under Section (H) of the American Innovation and Manufacturing Act, which establishes the Emissions Reduction and Reclamation Program.The final rule, under subsection (h), "Management of Regulated Substances" establishes an Emissions Reduction and Reclamation Program to reduce emissions of climate-damaging HFCs from air conditioner and refrigeration systems and maximizes the amount of HFCs that can be reclaimed. The EPA has been authorized by the AIM Act to address hydrofluorocarbons in three main ways: 1) phasing down their production and consumption; 2) promulgating certain regulations for purposes of maximizing reclamation and minimizing releases of HFCs from equipment and ensuring the safety of technicians and consumers; and 3) facilitating the transition to next-generation technologies through sector-based restrictions. Among its provisions, the final rule requires: Leak repair for certain appliances, Use of automatic leak detection systems for certain new and existing appliances; A standard for reclaimed HFC refrigerants; Servicing and/or repair of certain refrigerant-containing equipment with reclaimed HFCs; Initial installation and servicing and/or repair of fire suppression equipment with recycled HFCs; Recovery of HFCs from disposable cylinders prior to disposal; and Recordkeeping, reporting, and labeling. Brian F. Coleman, CEO of Hudson commented, "With this final rule, the EPA has finalized the third important pillar from the AIM Act, the primary focus of which was to reduce leak rates and promote the growth in reclamation. We are pleased that the EPA now provides a standardized definition of what constitutes the designation of reclaimed refrigerants and has provided sector mandates for the use of reclaimed refrigerants. The EPA initiatives outlined in this rule making, combined with the findings from the RMI report we sponsored which provided scientific support for the environmental benefits of using reclaimed refrigerants versus continuing the production and use virgin refrigerant, will set the stage for both mandatory and voluntary uses of reclaimed refrigerants particularly in the servicing sectors. We appreciate the EPA's dedicated efforts in finalizing the Refrigerant Management and Reclaim rule and look forward to working with our industry partners to promote practices to adopt refrigerant emission controls that are both environmentally and economically beneficial."

09:18 EDT MaxLinear teams with Rochester Electronics for ongoing lifecycle support - MaxLinear has partnered with Rochester Electronics to provide ongoing lifecycle management and customer support for their SHDSL product portfolio. Rochester Electronics, is the world's largest continuous source of semiconductors, offering 100% authorized, traceable, certified, and guaranteed devices. Rochester is focused on extending the availability of obsolete lifecycle products, along with providing support for active lifecycle products. MaxLinear has been a leading company in the SHDSL market for over ten years. Their solutions have been utilized in numerous mature telecom and industrial systems, including access networks, customer premise equipment, and industrial networks. The devices offer a wide range of functions, such as: Point-to-Multipoint and SHDSL party line, etc..."

09:15 EDT Sinclair & The Portland Trail Blazers launch Rip City Television Network - The Portland Trail Blazers have announced a new era of Trail Blazers Broadcasting, reaching an agreement with Sinclair Broadcast Group to launch the Rip City Television Network, a network of affiliates throughout the Pacific Northwest to serve as the new television home of Trail Blazers, and the launch of a new, paid, subscription-based direct-to-consumer DTC streaming service,BlazerVision, starting with the 2024-25 season. The announcement marks the first time in Trail Blazers history that a majority of games will be available to fans via easy-to-access over-the-air television...Fans within the Trail Blazers local broadcast market will have easy access to watch all local and non-exclusive nationally televised games across Sinclair's family of local over-the-air television stations in Portland, KATU and KUNP. Games will be accessible via an over-the-air antenna or a local cable or satellite provider that carries KATU and KUNP. k.

09:12 EDT U.S. Steel receives ResponsibleSteel Site Certification - U.S. Steel announced it is the first steel company in the world to qualify to sell its products as ResponsibleSteel Certified Steel at its Big River facility in Osceola, Arkansas. Big River received the first ResponsibleSteel Site Certification in North America in 2022.

09:09 EDT BlackLine appoints Henshall to its board of directors - BlackLine announced the appointment of David Henshall to its Board of Directors. Henshall spent nearly 20 years in various executive roles at Citrix, most recently as President and Chief Executive Officer. During his tenure, he played a critical role in accelerating Citrix's cloud transition and enhancing the company's operational performance. Prior to his role as CEO, he served as Chief Operating Officer and Chief Financial Officer.

09:07 EDT Cipher Mining announces the closing of acquisition of Barber Lake 300MW site - Cipher Mining announced it has completed the acquisition of the recently announced Barber Lake site in West Texas for a cash payment of $67.5 million and a variable fee of $3/MWh for the initial five years after the energization of the site. The site features 300 MW of front-of-the-meter capacity, a newly constructed, fully energized, high-to-mid voltage substation, and all necessary regulatory approvals. As part of the transaction, Cipher has acquired the 250 acres of land surrounding the substation and completed agreements necessary to participate in the ERCOT market.

09:06 EDT Mullen Automotive CEO provides video update to shareholders - Mullen Automotive announces a video update for shareholders released today and provided by Mullen CEO and chairman, David Michery. The video was released on Tuesday, Sept. 24, 2024, at 9 a.m. ET, and is available to view here on Mullen's official YouTube channel and MullenUSA.com. "Our group of companies, including Bollinger Motors and Mullen Advanced Energy Operations, continue to work towards meeting milestones and growing sales and I remain optimistic that the Company success will continue despite the challenges associated with our stock price," said David Michery, CEO and chairman of Mullen Automotive.

09:06 EDT Smartsheet to be acquired by Blackstone, Vista Equity for $56.50 per share - Smartsheet (SMAR) announced that it has entered into a definitive agreement to be acquired by funds managed by Blackstone (BX) and Vista Equity Partners in an all-cash transaction valued at approximately $8.4B. Under the terms of the agreement, the buyers would acquire all the outstanding shares held by Smartsheet shareholders for $56.50 per share in cash upon the closing of the proposed transaction. This price represents a premium of approximately 41% to the volume weighted average closing price of Smartsheet stock for the 90 trading days ending on July 17, the last full trading day prior to media reports regarding a possible sale transaction involving the company, and a 16% premium to the highest closing stock price over the last 12 months ending July 17. The merger agreement for the transaction includes a 45-day "go-shop" period that expires on November 8. During this period, Smartsheet and its advisors will be permitted to actively solicit alternative acquisition proposals from certain third parties, and potentially enter into negotiations with other parties that make alternative acquisition proposals. The Smartsheet board of directors will have the right to terminate the merger agreement to accept a superior proposal, subject to the terms and conditions of the merger agreement. The transaction is currently expected to close in the fourth quarter of Smartsheet's fiscal year ending January 31, 2025, subject to the approval of Smartsheet's shareholders, the satisfaction of required regulatory clearances and other customary closing conditions. The Smartsheet board unanimously approved the merger agreement and recommends Smartsheet shareholders vote their shares in support of the transaction at a special meeting of shareholders to vote on the transaction. Upon completion of the transaction, Smartsheet's Class A common stock will no longer be listed on any public market and Smartsheet will become a privately held company. The company will continue to operate under the Smartsheet name and brand.

09:05 EDT STMicroelectronics introduces fourth-gen STPOWER SiC MOSFET technology - STMicroelectronics is introducing its fourth generation STPOWER silicon carbide MOSFET technology. The Generation 4 technology brings new benchmarks in power efficiency, power density and robustness. While serving the needs of both the automotive and industrial markets, the new technology is particularly optimized for traction inverters, the key component of electric vehicle powertrains. The company plans to introduce further advanced SiC technology innovations through 2027 as a commitment to innovation.

09:02 EDT Taboola extends partnership with Xiaomi's International - Taboola announced an expanded partnership with the International Internet Business Department of Xiaomi, one of the world's largest consumer electronics manufacturers. Under the partnership, Xiaomi will utilize Taboola News to power recommendations in new ways across their devices in several markets globally. Taboola News brings recommendations from Taboola's large publisher network directly into offerings from mobile carriers and device manufacturers, including smartphone screens and web browsers.

08:55 EDT Smartsheet trading halted, news pending

08:49 EDT CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - Czechoslovak Group or CSG, anindustrial holding company reaffirmed its commitment to successfully completing the transaction with Vista Outdoor to acquire The Kinetic Group for $2.15 B and invest $150M in Revelyst or CSG Transaction. CSG urges all Vista Outdoor stockholders to vote in favor of the CSG Transaction at Vista Outdoor's October 9th special meeting. CSG will not agree to any further adjournment of the Vista Outdoor special meeting and reiterates that October 9th is the last possible date for Vista Outdoor to hold its special meeting of stockholders ahead of the October 15th termination date in the merger agreement. Michal Strnad, Chief Executive Officer and the owner of CSG, commented, "We are committed to executing our fully financed transaction with Vista Outdoor, which we believe maximizes value for Vista Outdoor stockholders. With the October 15th termination date for the transaction fast approaching, the upcoming October 9th special meeting will be the last and final opportunity for Vista Outdoor stockholders to vote to receive $2.15 billion in cash value for The Kinetic Group and shares of Revelyst - in which CSG has committed to invest $150 million for a 7.5% stake." ..."We remain open minded and are working in good faith with the Private Equity Firm and Vista Outdoor to see if a mutually beneficial outcome can be achieved; however, we continue to have serious concerns with the Private Equity Firm's latest proposal. While we will continue to engage with the Private Equity Firm, there remain notable challenges that need to be overcome."

08:47 EDT Foresight Autonomous signs strategic agreement with leading AI company - Foresight Autonomous Holdings announced the signing of a multi-phase strategic cooperation agreement with China Design Group, a $1 billion annual revenue Chinese technology company offering smart transportation solutions using IoT, 5G, and AI for urban planning and intelligent systems. CDG will leverage its expertise to lead the marketing and sales efforts of the intelligent traffic systems in mainland China, while Foresight will drive these initiatives in key international territories, focusing on Japan, South Korea, Europe, and the United States.

08:45 EDT Catheter Precision receives Chinese patent for LockeT - Catheter Precision has received notification of the issuance of its first LockeT patent in the country of China. Locket is a suture retention device used in the closure of percutaneous catheter access sites during any number of catheter procedures including electrophysiology, structural heart, and vascular surgery procedures. Locket is currently sold in the US and select international territories. Catheter Precision is awaiting CE mark certification, expected in the first quarter of 2025, which opens up the large market of European countries.

08:44 EDT Evofem Biosciences files proxy for stockholder approval of acquisition by Aditxt - Aditxt (ADTX) announced that its acquisition target, Evofem Biosciences (EVFM) filed a preliminary proxy to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, with Aditxt and Adifem, a wholly-owned subsidiary of Aditxt Adifem pursuant to which, and on the terms and subject to the conditions thereof, Adifem will merge with and into Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt. Assuming the proposal is approved by Evofem stockholders and other closing conditions are met, including but not limited to the Company raising sufficient capital to fund its obligations at closing, the companies are targeting closing the transaction in the fourth quarter of 2024. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

08:42 EDT Surrozen earns $10M milestone payment in Retinal Diseases collaboration - Surrozen announced that Boehringer Ingelheim will further develop SZN-413 to advance the compound and prepare it for clinical testing. Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. The milestone achievement triggers a $10 million payment to Surrozen as part of the agreement. "We are excited that Boehringer has decided to move forward with the development of SZN-413 based on the completion of the initial period of joint research," said Craig Parker, President and Chief Executive Officer of Surrozen. "With the strong genetic, experimental and clinical evidence of the role for Fzd-4 specific Wnt signaling in the retinal vasculature, we look forward to the further evaluation of this novel therapeutic approach to address one of the most urgent medical needs for people with retinal disease."

08:41 EDT Reservoir Media announces publishing deal with Snoop Dogg, Death Row Records - Reservoir Media announced new publishing deals with renowned rapper Snoop Dogg and Death Row Records. The deals include domestic publishing for Snoop's entire catalog of hits and future works, as well as the publishing catalog of Snoop's Death Row Records.

08:40 EDT Zoned announces launch of Topgolf Universe on Fortnite's UEFN platform - Zoned announce the recent launch of the Topgolf Universe on Fortnite's UEFN platform. Topgolf is breaking new ground in virtual entertainment, launching an immersive experience on Fortnite's UEFN platform. For the first time ever, players can dive into a fully interactive version of the iconic Topgolf experience-teeing off, racing, and exploring-all within Fortnite's expansive universe. Topgolf and Fortnite have come together to represent the growing convergence of entertainment, sports, and gaming, redefining how brands can engage with their audience

08:39 EDT Ensysce Biosciences to present at upcoming meetings - Ensysce Biosciences announced its participation in two upcoming meetings in October 2024. October 5, 2024: New data will be presented in a poster session in collaboration with Sygnature Discovery at the Society for Neuroscience meeting in Chicago in the session for Addictive Drugs: Drug Tolerance, Dependence, and Toxicity.The poster entitled "Methadone ameliorates the effects of morphine withdrawal in a modified rat model of physical dependence" is the first study of its kind in a pre-clinical model to evaluate the efficacy of novel agents for treating Opioid Use Disorder.OUD affects 16 million people worldwide and can be attributed to 500,000 deaths each year. OUD is characterized by intense cravings for opioids and severe withdrawal effects if an opioid cannot be found. Methadone is a common agent used to reduce these cravings yet can be abused. OUD has unwanted cardiovascular side effects and due to varied pharmacology can lead to overdose and death. Ensysce has been applying its Trypsin Activated Abuse Protection technology to develop novel methadone analogues with reduced cardiovascular side effects and reduced abuse potential. Sygnature Discovery employs relevant rodent models, knowledge about applicable and sensitive endpoints, and state-of-the-art technologies in the assessment of behavioral effects of novel drug candidates. October 16, 2024: Dr. Lynn Kirkpatrick, CEO of Ensysce, has been invited as an Expert Speaker at the Formulation & Delivery US 2024 meeting in San Diego, CA to present "TAAP and MPAR - Delivering Prescription Drugs Safely with Added Oral Overdose Protection". The presentation will highlight the versatility of the TAAP and MPAR platforms, and showcase Ensysce's lead products, PF614 and PF614-MPAR. The Fast Track and Breakthrough Therapy designations from the FDA demonstrate the uniqueness of these approaches to deliver effective drugs more safely and efficiently.

08:37 EDT Banzai announces $24.8M debt payoff, restructuring agreements - Banzai International entered into agreements with lenders and service providers to write off up to $5.6 million of outstanding liabilities and restructure a further $19.2 million of its existing debt obligations, improving the Company's overall financial position by amending certain credit obligations and extending the maturity of certain debt facilities. Including the previously executed Cantor Fitzgerald fee restructuring, this represents a total of $28.8 million in anticipated reduced and restructured liabilities. Banzai has reached an agreement with creditors to eliminate approximately $15.3 million of debt via a combination of private placement and debt restructuring, with participation from insiders including Alco Investment Company. As part of the debt restructuring, a term loan with CB BF Lending is being converted to a fixed-price convertible with a maturity date extended to February 19, 2027, a two-year extension. This substantially increases the cash runway and improves working capital; we believe it will also enable the Company to achieve its near-term growth initiatives.

08:36 EDT SRM Entertainment, Suretone Pictures announce media agreement - SRM Entertainment's SRM and Suretone Entertainment's Suretone Pictures are in negotiations to form an alliance capitalizing on Suretone Pictures' film productions, tv content creation, existing library and distribution strength alongside SRM's ongoing merchandise, manufacturing and distribution businesses as engaged in providing its services to the major film studios. The initial transaction was closed on September 3, 2024 with the transfer of the first of several valuable film assets transferred by Suretone Pictures to SRM. SRM and Suretone Entertainment's Suretone Pictures are engaged in far-reaching discussions to jointly create a new media company using certain assets of Suretone Pictures as the two companies intend to come together to build a multi-film asset and IP based library with an innovative plan towards distribution, merchandising and production.

08:36 EDT Roadzen insiders, shareholders agree to extend lock-up for additional year - Roadzen announced that all its major shareholders known to own more than 5% of the Company's common stock, holders of a majority of its shares held by other shareholders and all company insiders have agreed to extend their lock-up agreements by another twelve months, to September 20, 2025. This represents shareholders owning over 56 million shares that were originally scheduled to be released from lock-up on September 20, 2024, pursuant to the lock-up agreements entered into in connection with the Company's initial business combination.

08:34 EDT Cellebrite announces patent for Remote Mobile Collection - Cellebrite announced the patent for Remote Mobile Collection, which equips corporate investigators with immediate, targeted remote data collection - saving them time and money. In today's hybrid work environment, this newly patented technology - available in Cellebrite's SaaS platforms Endpoint Mobile Now and Endpoint Inspector - delivers high value, supporting rapid data collection and offers greater convenience to the device's consenting owner, who can keep it during collection rather than return it to a corporate office.

08:33 EDT Anixa Biosciences announces Phase 2 study for breast cancer vaccine - Anixa Biosciences announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by a grant from the U.S. Department of Defense. The proposed Phase 2 trial will evaluate the efficacy of the vaccine administered in the neoadjuvant setting, in combination with chemotherapy and Keytruda. Compared with primary prevention, the development path for breast cancer treatment is expected to have a shorter path to approval. The key objectives of the trial include evaluating the immunological response to the vaccine and comparing clinical efficacy of standard of care therapy alone with the vaccine plus standard of care therapy. The trial is expected to commence in 2025 and is projected to last approximately two to three years. Immunological responses to the vaccine will be made available as the trial advances.

08:32 EDT LightPath secures $3.5M follow-on order - LightPath Technologies announced a $3.5M follow-on order to provide advanced infrared optics for the F-35 combat aircraft program. Sam Rubin, President & CEO of LightPath, said: "This third order from a tier-1 defense customer follows an initial order of $2.5 million in December 2022 and a follow-on order of $3.4 million in October 2023 - validating our capability to meet intensive qualification standards and deliver a unique value proposition to critical military programs. We expect to realize this revenue over the course of 12 months and believe there remains significant growth potential within the F-35 program alone."

08:26 EDT Savaria executive chairman completes secondary sale of securities - Savaria announced Marcel Bourassa, Executive Chairman of Savaria, has completed the sale of 2,000,000 common shares of Savaria. The Common Shares were sold through the facilities of the Toronto Stock Exchange. Following the sale of Common Shares, Mr. Bourassa will continue to be the largest shareholder of Savaria with an approximately 16.09% equity interest. "After 35 years of leadership at Savaria, I am proud of our accomplishments of building a team that has brought Savaria to the next level," said Mr. Bourassa. The proceeds from the sale of Common Shares are for personal reasons, for family estate planning purposes and in support of philanthropic endeavors. Mr. Bourassa may, from time to time, increase or decrease his investment in Savaria through market transactions, private arrangements, treasury issuances or otherwise. On September 23, 2024, Mr. Bourassa completed the sale of 2,000,000 Common Shares beneficially owned by Les Elevateurs Savaria through the TSX, which were sold at a price of $20.63 per share, for an aggregate consideration of $41,260,000

08:25 EDT Computer Modelling Group launches Focus CCS tool - Computer Modelling Group is announcing the launch of Focus CCS, a purpose-driven simulation tool designed to accelerate the preliminary selection and validation process for CO2 storage sites. With its intuitive interface and guided workflows, Focus CCS enables engineers to quickly and accurately evaluate risks, predict safe CO2 storage capacities, and expedite the process leading up to permitting and regulatory approval. Focus CCS is now available worldwide and will make a critical contribution to getting more CCS projects into operation - supporting the global goal of progressing towards net zero.

08:23 EDT Danone North America proposes to acquire Lifeway Foods for $25 per share - In a regulatory filing last night, Danone North America PBC (DANOY), which holds a 23.4% stake in Lifeway Foods (LWAY), disclosed that on September 23, Danone North America PBC sent a letter, proposing to acquire all of the outstanding shares of Lifeway common stock not currently held by the reporting persons for a purchase price of $25.00 per share in cash. "The transaction would be wholly funded in cash from existing cash reserves of the Reporting Persons and is not contingent on any financing requirements. The proposal is subject to the completion of due diligence and negotiation of definitive agreements... The Reporting Persons intend to engage in discussions with the Issuer regarding the Proposed Transaction," the filing stated. Reference Link

08:23 EDT Lotus Technology unveiles breakthrough in intelligent driving services - Lotus Technology announced a major breakthrough in its intelligent driving services, marking a revolutionary step forward in the automotive industry. This advancement reflects Lotus Tech's unwavering dedication to integrating cutting-edge technology into its world-renowned luxury vehicles, redefining the driving experience for its customers. Recent performance data from the Company's exclusive user app highlights that Lotus Tech has achieved a remarkable milestone: a single intelligent driving session for a user reaching up to 533 kilometers1 without any intervention, which is nearly the maximum range for single charging. This underscores the Company's leadership in delivering exceptional performance and reliability through its advanced intelligent driving systems. Beyond these impressive figures, users are showcasing deep engagement with the brand's intelligent driving features. Data from Lotus Tech's user app also reveals that individual customers are logging substantial intelligent driving mileage. The highest recorded single-user monthly intelligent driving mileage has reached 3,427 kilometers, with total cumulative intelligent driving mileage for a single user hitting an extraordinary 36,342 kilometers.

08:21 EDT Trxade Health announces name change to Scienture Holdings - TRxADE Health announced that the Company has changed its name to "Scienture Holdings, Inc." Effective as of September 23, 2024, the Company's stock is now trading on the Nasdaq Stock Market LLC under the new ticker symbol "SCNX". Scienture Holdings, Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Our products are in development across therapeutic areas and indications, and cater to different market segments and channels.

08:20 EDT Barinthus Biotherapeutics initiates Phase 1 clinical trial of VTP-1000 - Barinthus Biotherapeutics announced the initiation of its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. The randomized, placebo-controlled clinical trial, which includes a controlled gluten challenge, will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000. The Phase 1 AVALON trial aims to enroll 42 participants with celiac disease and will be conducted in two parts: a randomized double-blind placebo controlled single ascending dose, SAD, part, followed by a randomized double-blind placebo-controlled multiple ascending dose part, incorporating a controlled gluten challenge to assess the impact of VTP-1000 administration on patients' exposure to gluten.

08:20 EDT IceCure Medical's cryoablation system shows 96% recurrence free rate - IceCure Medical announced the publication of an article in the Annals of Surgical Oncology, the official journal of the Society of Surgical Oncology presenting the results of IceCure's ICE3 trial for liquid nitrogen based cryoablation of small, low-risk, early-stage malignant breast tumors as an alternative to surgery. Lead author of the study Dr. Fine commented, "Our analysis of the trial's primary outcome, ipsilateral breast tumor recurrence at 5 years, suggests that cryoablation with ProSense is safe and effective for patients with early-stage low-risk breast cancer. At the 5-year follow-up, we observed local control similar to surgical standard of care. Cryoablation may be considered as an alternative to lumpectomy in this select population if followed by appropriate adjuvant treatment. Future study within a clinical trial or registry is encouraged to confirm cryoablation as a viable alternative to surgical excision." With a mean follow-up period of 54.16 months for the total population of the ICE3 trial, the trial's primary outcome, ipsilateral breast tumor recurrence or IBTR rate at 5 years was 4.3% and breast cancer survival was 96.7%. Of the 124 patients who received cryoablation and endocrine therapy, the IBTR was 3.7%, resulting in a recurrence-free rate of 96.3%. No serious device-related adverse events were reported. 100% of patients and treating physicians were satisfied with the cosmetic outcome.

08:18 EDT Aligos Therapeutics appoints Hardean Achneck as CMO - Aligos Therapeutics (ALGS) announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Most recently, Dr. Achneck served as the Senior Vice President and Head of Clinical Development at Pliant Therapeutics (PLRX) where he oversaw all clinical programs, including those in hepatic diseases.

08:16 EDT Brera Holdings approved to dual list internationally on Upstream - Brera Holdings has been approved to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading becomes available on Upstream on Tuesday October 1st at 10:00am ET under the ticker symbol 'BREA'.

08:15 EDT Aemetis calls on CARB to implement 15% ethanol blend in gasoline - Aemetis called for the California Air Resources Board to immediately implement a 15% ethanol blend in gasoline to reduce gas prices for California consumers and reduce greenhouse gas emissions from motor vehicles. California stands alone among the 50 states in not adopting a 15% blend of fuel ethanol. The US EPA approved E-15 for use in light duty vehicles in 2011, and 49 other states have adopted a 15% ethanol blend. California still mandates a 90% petroleum blend in every gallon of gasoline. In response to Governor Newsom calling a special session of the state legislature, the State Assembly is currently holding hearings regarding the need for lower fuel prices in California. An obvious solution is to allow consumers to purchase lower cost, cleaner burning, domestically produced renewable fuel instead of mandating higher cost, polluting imported petroleum fuel. A recent study by UC Berkeley and US Naval Academy economists found that allowing an E-15 blend could save California drivers $2.7 billion at the pump annually, which translates into approximately $0.20 per gallon every time a motorist fuels their car. A typical California household would save about $200 per year on gasoline expenses, and for many lower income residents of the Golden State, that money could be spent on items like childcare, groceries, or prescription medications. Moving to an E-15 blend would have an immediate impact on California's environment as ethanol is derived from renewable sources and emits 46% fewer air pollutants than gasoline. According to the Environmental and Energy Study Institute, the US transportation sector accounts for 27 percent of US greenhouse gas emissions. Increasing California's ethanol blend would reduce emissions and likely reduce gasoline usage in the state, while providing an immediate and measurable benefit to the state's ambitious goal of reaching net carbon neutrality by the year 2045. A study commissioned by CARB found that adopting E-15 in the state could cut emissions of tailpipe pollutants such as particulate matter and carbon monoxide, which cause air quality and human health problems.

08:13 EDT ABM expands charger portfolio with Samsung C&T Charging Solutions partnership - ABM (ABM) announced a distributorship agreement with Samsung (SSNLF) C&T Charging Solutions, making ABM an authorized distributor and servicer of EVSIS-branded DC Fast Chargers. Samsung C&T Charging Solutions is an equity partner of the Korean DC Fast Chargers manufacturer EVSIS, which is entering the United States market.

08:12 EDT Aurinia Pharmaceuticals announces Japan MHLW approval for voclosporin - Aurinia Pharmaceuticals announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil, or MMF, to treat lupus nephritis, or LN. The company's collaboration partner, Otsuka Pharmaceutical, filed the new drug application, or NDA, with Japanese regulatory authorities in November 2023. The approval is based on data from the AURORA Clinical Program, which included a 12-month, Phase 3, double-blind, randomized-controlled study, as well as a two-year extension study, assessing the efficacy and safety of voclosporin with MMF and low-dose glucocorticoids, compared to MMF and low-dose glucocorticoids alone, in LN patients. Aurinia and Otsuka entered a collaboration and licensing agreement in December 2020 for the development and commercialization of oral voclosporin in the EU, Japan, the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein, and Ukraine. As part of the agreement, Aurinia is eligible to receive a payment of $10M upon approval in Japan along with low double-digit royalties on net sales once launched. The company will supply product to Otsuka to support the launch under the associated commercial supply agreement on a cost-plus basis.

08:12 EDT Paycor HCM unveils features to redefine time-off managment - Paycor HCM announced a suite of innovative features designed to transform time-off management for the modern workforce. These cutting-edge additions to Paycor's HCM platform streamline time-off operations through automation, real-time visibility and proactive controls to drive efficiency and promote employee well-being. Paycor now offers seamless integration of time-off requests with scheduling, providing leaders with real-time visibility of these requests while building schedules. This feature allows for enhanced productivity and coordination through comprehensive visibility into time-off schedules for employees and leaders. Time Off Advisor provides employees with peak time visibility through blackout dates and balance forecasting, enabling better planning and communication with managers for time-off planning. Paycor Paths offers bite-sized training to empower leaders to recognize and prevent causes of burnout while easily accessing time-off balances and requests to identify potentially at-risk employees via the COR Leadership Dashboard.

08:10 EDT Standard BioTools: SomaScan includes protein measurements on broad sample range - Standard BioTools announced that the SomaScan 11K Platform now includes protein measurements on a broader range of sample types, including cerebrospinal fluid, aqueous humor, tissue homogenates and cell lysates. The SomaScan Platform provides the largest number of protein measurements and the greatest number of orthogonally confirmed protein reagents in the proteomics industry -11,000 protein measurements simultaneously from sample volumes as low as 55 microl-giving researchers access to half of the human proteome in just one assay. "These new sample types expand the SomaScan11K Platform's ability to provide important biological insights, supporting translational medicine by advancing research findings into disease causation, clinical pharmacology and drug development," said Standard BioTools Chief Medical Officer Stephen A. Williams, MD, PhD. "The use of high-throughput proteomics in cerebrospinal fluid for neurodegenerative disease research, for example, is key to providing information on biological changes occurring in the brain. The SomaScan Platform's sensitivity to these changes is expected to give researchers a wealth of mechanistic neurological data." The SomaScan Platform is the only proteomic approach on the market that scales. The precision of the SomaScan Assay has been maintained or improved across all versions, up to and including the most recent release covering 11,000 protein measurements-a challenge that antibody-based assays have failed to overcome. The platform offers low coefficients of variation, a median around 5%, which means the SomaScan Assay can provide more statistical power to make discoveries.

08:08 EDT Comcast: CommScope's FDX DOCSIS amplififier now live serving customers - Comcast (CMCSA) and CommScope (COMM) announced that for the first time CommScope's Full Duplex or FDX DOCSIS amplifier is now live serving customers in Comcast's network. With the deployment of FDX amplifiers, Comcast will be able to seamlessly deliver multi-gig symmetrical services along with enhanced reliability, security and performance, to customers served by the vast majority of its current network architecture. "At SCTE Expo last year we were excited to announce the first deployment of multi-gig symmetrical service to Comcast customers, and in the months since we have turned scaled DOCSIS 4.0 FDX into a reality," said Elad Nafshi, Chief Network Officer, Comcast. "With this first CommScope Full Duplex or FDX, DOCSIS amplifier live in our network, we are positioned to accelerate the pace of our FDX DOCSIS 4.0 deployment. This pioneering smart amplifier will enable us to deliver multi-gig symmetrical services and leverage industry-first imbedded AI capabilities to deliver unprecedented intelligence, service automation and reliability across our network." Since launching FDX DOCSIS 4.0 in October 2023, Comcast has scaled the offering to more than one million homes across six markets and expects to continue to accelerate the pace of activation. Amplifiers are a critical component to realizing FDX DOCSIS 4.0 across Comcast's footprint, with the current network architecture utilizing up to a six-amplifier cascade to reach customers with multi-gig symmetrical services. With this first successful deployment of CommScope's FDX amplifier, Comcast has a clear path to delivering an unparalleled network experience to homes and businesses across the U.S.

08:07 EDT Matthews announces pricing of senior notes - Matthews International has priced its previously announced private offering of $300 million aggregate principal amount of its 8.625% senior secured second lien notes due 2027. The Notes will pay interest semi-annually in arrears, on April 1 and October 1 of each year, beginning on April 1, 2025. The Notes will mature on October 1, 2027, unless earlier redeemed or repurchased. The Notes offering is expected to close on September 27, 2024, subject to customary closing conditions. The Company intends to use the net proceeds of the offering, together with borrowings under the Company's senior credit facility, to redeem all of its outstanding 5.25% senior notes due December 1, 2025 on or about October 24, 2024, and to pay accrued and unpaid interest on the Existing 2025 Notes to, but not including, the date of redemption, and to satisfy and discharge the indenture governing the Existing 2025 Notes.

08:06 EDT electroCore engages FNK IR to execute expanded IR program - electroCore announced that it has engaged FNK IR, an institutionally focused investor relations consulting firm, to develop and deploy an expanded outreach and communications program.

08:05 EDT Seelos Therapeutics selected by U.S. Army to evaluate SLS-002 in PTSD - Seelos Therapeutics signed a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity - USAMMDA - to supply SLS-002 - intranasal racemic ketamine - for the U.S. Department of Defense's Military and Veterans Adaptive Platform Clinical Trial to evaluate its potential for treatment of post-traumatic stress disorder. Dosing of the SLS-002 cohort is expected to commence prior to the end of 2024. The trial is funded by the DOD's Defense Health Agency and led by USAMMDA's Warfighter Readiness, Performance, and Brain Health Project Management Office. The Phase II study that will evaluate the safety, tolerability, and efficacy of multiple pharmacotherapeutic interventions in active-duty service members and veterans with PTSD. Endpoints include the incidence of new or worsening suicidal thoughts or behaviors. In addition, the trial is evaluating several biomarkers associated with PTSD and assessing treatment safety and tolerability.

08:05 EDT NetApp partners with Nvidia on AI data vision - NetApp (NTAP) unveiled an advanced generative AI data vision and end-to-end integrated solutions that combine Nvidia (NVDA) AI software and accelerated computing with NetApp intelligent data infrastructure for enterprise retrieval augmented generation, or RAG, to power the future of agentic AI applications. This will bring new capabilities to the NetApp ONTAP unified storage operating system that can leverage a new NetApp global metadata namespace to unify data stores for the tens of thousands of enterprises that trust NetApp for their data infrastructure. It opens up exabytes of enterprise data stored across clouds and on-premises infrastructure to drive RAG capabilities that can put enterprises' entire data estate to work, accelerating next-generation agentic AI applications. The solution brings together proven NetApp AIPod architecture with NetApp ONTAP and the NetApp BlueXP unified control plane, with Nvidia NeMo Retriever and NIM microservices, which are part of the Nvidia AI Enterprise software platform.

08:04 EDT Presto Automation announces sale process backed by lender financing - Presto Automation announced an injection of significant operating capital from its senior secured lenders, led by Metropolitan Partners Group. This capital will help support the Company and stabilize its ongoing operations during a sales process for the Company's business and assets, and was provided by the lenders following an uncontested notice of default to the Company from Metropolitan. Metropolitan, with the help of its sale agent, Rock Creek Advisors, will be running a sale process under Article 9 of the Uniform Commercial Code to obtain the highest and best value for the Company's business and assets. The Company expects that a successful sale will result in a streamlined capital structure and improved financial flexibility. Current shareholders of Presto Automation Inc. are not expected to receive any payment for their shares following the sale process, and Presto Automation Inc. will be wound up. Over the past several months, Presto's Voice AI efficiency has shown significant improvement and accuracy, continuing to demonstrate that its cutting-edge automation solutions enhance efficiency and improved guest experience for its restaurant partners. Presto is currently expanding with significant QSR chains, which will bring its AI technology to approximately 750 additional restaurants when fully expanded. The sale process will begin September 24th, 2024 and is expected to conclude in November 2024

08:02 EDT ViaSat awarded $33.6M U.S. Air Force contract - Viasat was awarded a $33.6M contract including options from the U.S. Air Force Research Laboratory - AFRL - under the Defense Experimentation Using Commercial Space Internet program to develop and deliver Active Electronically Scanned Array - AESA - systems to enable resilient satellite communications for tactical aircraft, including rotary wing platforms. Viasat will use its commercial AESA technology, as well as its integration and radio frequency integrated circuits expertise, to develop a new phased array antenna that can support resilient communications for tactical aircraft by enabling connections across different frequencies, orbits and commercial networks.

07:55 EDT I3 Energy says ISS, Glass Lewis recommend vote for Gran Tierra transaction - I3 Energy (ITEEF) noted that independent proxy advisors, Institutional Shareholder Services, and Glass Lewis & Co., have both recommended that shareholders vote FOR the proposed acquisition of i3 Energy by Gran Tierra Energy, Inc (GTE) at the upcoming Court Meeting and General Meeting on 7 October. The Board of i3 Energy also reiterates its unanimous recommendation for shareholders to vote in favour of the proposed acquisition for the following reasons: Gran Tierra's offer represents a premium of 49% to the closing price on the 16th of August 2024, the day before the offer was announced and a premium of 49.7% to the 30-day volume weighted average price, ending the 16th of August 2024. The offer value compares favourably to comparable company valuations and transactions across a range of metrics. The offer represents the highest share price of the Company since October 2023. The cash payment accelerates returns and is equivalent to over 10 years of dividends at the current quarterly dividend payment. i3 Energy shareholders will own up to 16.5% of the pro-forma Gran Tierra company, which brings increased scale and financial capacity to extract value from i3 Energy's Canadian undeveloped resource base; particularly, its key Simonette Montney asset - Gran Tierra's financial resources are expected to be deployed to accelerate its development and i3 shareholders will benefit from this through their ongoing shareholding in the Combined Group. Beyond the development of key assets in i3's portfolio, i3's shareholders will gain exposure to Gran Tierra's diverse portfolio of 100% owned and operated oil weighted production and development assets and a large inventory of exploration prospects. The pro-forma company will be able to allocate capital to the most profitable projects from a much larger opportunity set. The growth potential and optionality in the pro-forma business will be considerably greater than in i3 Energy as a standalone entity. Gran Tierra is an active operator and has many projects that if successful, will deliver incremental near-term production and cashflows. The transaction will combine two high quality teams with a strong track record of success in the jurisdictions in which they operate. We believe the combination will result in enhanced performance across the business units and generate beneficial operational and cost synergies.

07:48 EDT Ecopetrol announces name change for offshore exploration projects - Ecopetrol informs that, in compliance with the ruling issued by the Fourth Labor Court of the Santa Marta Circuit, the names "Uchuva" and "Tayrona" will no longer be used to refer to its offshore exploration projects in the Colombian Caribbean, nor any project in which the company is involved. This mention of the former names is made only once to comply with the court's order. In collaboration with Petrobras, Ecopetrol's partner in these projects, it has been agreed that the first project will now be referred to as SIRIUS, and the second as GUA-OFF-0.

07:41 EDT Vista Outdoor shareholder Gates Capital intends to vote against CSG proposal - Vista Outdoor shareholder Gates Capital Management, an alternative asset manager that beneficially owns approximately 9.6% of Vista's shares of common stock, issued a statement encouraging Vista to finalize negotiations for an all-cash offer for the company and reiterating its intention to vote against the proposed sale of The Kinetic Group to the Czechoslovak Group, or CSG. Highlights of the statement include: "...independent proxy advisory firm ISS recommended that shareholders vote AGAINST the latest CSG proposal. We agree with the ISS recommendation and support its view that the best outcome for shareholders would be attained by selling both The Kinetic Group and Revelyst in a revised all-cash transaction. Recent public disclosures indicate that a private equity firm has recently offered $1.1B in cash for Revelyst, but that such a transaction would need to take place sooner rather than later since the firm would not have any interest in purchasing Revelyst after the closing of the currently proposed CSG transaction. We strongly believe that the currently proposed transaction with CSG to sell only The Kinetic Group is not in the best interest of shareholders as it would eliminate the possibility of subsequently selling Revelyst to this private equity firm. For this reason, we see no reason to support any transaction that doesn't include a comprehensive sale of the entire company".

07:38 EDT Electra Battery Materials submits request for appeal of Nasdaq determination - Electra announces that following receipt of notice from The Nasdaq Stock Market of noncompliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) on September 17, 2024, it has submitted a request for an appeal of Nasdaq's determination pursuant to the procedures set forth in the Listing Rules. The appeal hearing date has been set for November 5, 2024, and the Company's shares will continue to trade on Nasdaq until this date. If at any time before November 5, 2024, the bid price of the Company's shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Requirement and the appeal hearing will be cancelled. In the event the appeal is successful, the Company expects to receive additional time in which to regain compliance with the Minimum Bid Requirement. There can be no assurance that the appeal will be successful or that the Company will be able to regain compliance. This matter does not impact the listing of the shares on the TSX Venture Exchange.

07:37 EDT Electra achieves technical grade lithium carbonate in recycling program - Electra Battery Materials announced the achievement of greater than 99% purity, or technical grade, lithium carbonate product. These results further bolster the Company's ability to produce high-quality, technical and battery-grade products from its black mass recycling project. "Our proprietary hydrometallurgical process has demonstrated repeatedly that it can successfully produce high-quality, saleable products, now including lithium carbonate, along with nickel-cobalt MHP and graphite," said Electra CEO, Trent Mell. "This achievement of technical grade lithium carbonate at a plant scale may be the first such achievement in North America. It is critical we not only continue to develop the onshore supply chain, but also a closed-loop solution to battery recycling, as EV adoption rates increase. This year, we have received a C$5 million funding commitment from the Government of Canada to develop this next phase of our business, and results such as this will help drive that program forward as we look to scale up," Mell continued. "Our new joint venture with the Three Fires Group, Aki Battery Recycling, is another critical component in solidifying the future for Electra's recycling program, as it will provide a steady source of black mass for future continuous operations."

07:36 EDT Wave Life Sciences announces interim data fom ogoing Phase 2 FORWARD-53 study - Wave Life Sciences announced positive interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy, DMD, who are amenable to exon 53 skipping. The interim analysis was conducted after 24 weeks of 10 mg/kg dosing every two weeks, Q2W, and WVE-N531 demonstrated substantial dystrophin expression and that it was safe and well tolerated. Results from this interim analysis include: WVE-N531 was safe and well tolerated; Dystrophin results from a pre-specified analysis of ambulatory boys showed: Mean absolute muscle content-adjusted dystrophin expression was 9.0% and mean absolute unadjusted dystrophin expression was 5.5% of normal, The dystrophin expression was quantified from two isoforms consistent with those observed in Becker muscular dystrophy patients who display milder disease, 89% of ambulatory participants achieved muscle content-adjusted dystrophin levels of at least 5%.; WVE-N531 was detected in myocyte nuclei in all participants and in myogenic stem cells in the majority of participants; Participants showed multiple indicators of improvement in muscle health; The muscle tissue half-life of WVE-N531 is estimated to be 61 days

07:35 EDT Supernus announces ongoing collaboration with Busy Philipps - In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this fall about her ongoing journey with attention-deficit/hyperactivity disorder, bringing awareness to the often-overlooked symptoms of the condition in women and Qelbree, a non-stimulant ADHD treatment that has benefitted her. With summer over and the school year now in full swing, the fall season brings for many adults a return to normal routines or schedules, as well as an opportunity for a fresh start. Busy knows first-hand just how difficult getting 'back to schedule' can be for the approximately 10 million adults living with ADHD, who may be experiencing symptoms of inattention, hyperactivity/impulsivity, or both. She's sharing her story to help empower people, and especially women, living with ADHD to take action for a fresh start this fall and talk to their doctors about treatment options to help manage their condition.

07:33 EDT Draganfly receives military purchase order for its Commander 3XL - Draganfly announces that it has received a purchase order from TB2 Aerospace, TB2, for Commander 3XL Drones to be deployed with TB2 Drone Recharging Operational Payload System Pods, DROPS, within the DoD for various mission types. This order represents the beginning of the deployment and scaling of the DROPs system in conjunction with the Draganfly line of drones. "We are honored to be doing this exciting work with TB2 and to have been selected for this important work in the military logistics sector," said Cameron Chell, CEO of Draganfly. "Draganfly thrives at working to provide exceptional capabilities by integrating our line of drones, experience, and technology stack into mission profiles and use cases with our commercial and military partners-and doing it within time frames and at costs that few others can."

07:26 EDT AGF Management partners with Archer to support growth of SMA model business - AGF Management announced a partnership with Archer Holdco to help further grow its Separately Managed Accounts model business. AGF will leverage the technology capabilities and infrastructure of Archer, a technology-enabled service provider to the investment management industry.

07:20 EDT Nutriband receives China patent notice of allowance for Aversa - Nutriband has received a Notice of Allowance from the Chinese National Intellectual Property Administration for patent application entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA abuse deterrent transdermal technology. The Aversa abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, Australia, and China. Nutriband's AVERSA abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them. Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. Preliminary studies have shown that the coating is very difficult to scrape off and the technology has a patented immediate and extended-release profile which presents an additional layer of deterrence to prevent the aversive layer from easily being washed off in an attempt to separate the drug from the aversive agents.

07:14 EDT Applied Optoelectronics demonstrates 1.6T OSFP DR8 LPO module - Applied Optoelectronics is demonstrating its latest linear technology, the 1.6T OSFP DR8 LPO module, at the European Conference on Optical Communications 2024, setting a new level for high-speed networks by doubling the data rate of current interfaces. The 1.6T OSFP DR8 LPO module is designed to integrate with the Optical Internetworking Forum's CEI-224G Linear standard, enabling data transfer rates essential for supporting data intensive applications, including Artificial Intelligence,, machine learnings, and advanced data center operations. These integration capabilities address the current needs of today's network infrastructures and position businesses to scale and integrate future advancements for reliable performance.

07:12 EDT Denison Mines executes uranium interests option with Foremost for up to $30M - Denison Mines (DNN) has executed an option agreement with a Nasdaq listed company to be renamed Foremost Clean Energy (FMST), which grants Foremost an option to acquire up to 70% of Denison's interest in 10 uranium exploration properties. Pursuant to the transaction, Foremost would acquire such total interests upon completion of a combination of direct payments to Denison and funding of exploration expenditures with an aggregate value of up to approximately $30M. The transaction is structured to incentivize exploration activity, with Foremost required to invest a minimum of $8M in exploration expenditures to retain any interests in the properties and $20M in exploration expenditures to fully exercise the option. Collaboration with Foremost is expected to increase exploration activity on a portfolio of non-core Denison properties with the potential to increase the probability of discovery within Denison's vast Athabasca Basin exploration portfolio. Denison is to receive meaningful consideration in the form of an upfront payment in Foremost common shares, representing ~19.95% ownership interest in Foremost post transaction, cash or common share milestone payments, and up to $20M in project exploration expenditures. Denison retains direct interests in the optioned exploration properties and will become Foremost's largest shareholder, while also securing certain strategic pre-emptive rights to participate in future exploration success from the optioned properties. Denison currently has 100% ownership in all of the properties except for Hatchet Lake, which is subject to a joint venture agreement with Eros Resources, with Denison currently holding a 70.15% ownership interest. Foremost is expected to act as project operator during the term of the Option Agreement; however, Denison expects to leverage its significant team of technical experts based in its office in Saskatoon, Saskatchewan to support Foremost as it transitions to uranium exploration. Additionally, David Cates, President and CEO of Denison, is expected to join Foremost's Board of Directors.

07:11 EDT Foremost Lithium enters property acquisition agreement with Denison Mines - Foremost Lithium Resource & Technology (FMST) has executed a property acquisition agreement with Denison Mines Corp. (DNN), which grants Foremost an option to acquire up to 70% of Denison's interest in 10 uranium exploration properties, along with other ancillary agreements. Pursuant to the Transaction, Foremost will provide Denison with consideration, including cash, stock, and/or future exploration spending commitments by Foremost. The Transaction is subject to regulatory approvals. In connection with the Transaction, Foremost intends to change its name to "Foremost Clean Energy Ltd." Under the terms of the Option Agreement, Foremost may acquire up to 70% of Denison's interest in the Exploration Properties. Denison currently has 100% ownership in all of the properties except for Hatchet Lake, where Denison currently owns 70.15%, subject to a joint venture with Eros Resources Corp. In the case of Hatchet Lake, Foremost may earn up to a 51% interest in the joint venture, representing slightly over 70% of Denison's current ownership interest. The Option Agreement outlines three phases, as summarized below: Phase 1: To earn an initial 20% interest in the Exploration Properties, on or before October 7, 2024, Foremost's obligations include: Issuing 1,369,810 of the Company's common shares to Denison; Appointing one director to Foremost's Board of Directors immediately on the Effective Date; Appointing a Technical Advisor to Foremost at Denison's election; and Entering into an Investor Rights Agreement providing for, among other things: The appointment by Denison of up to two individuals to the board of directors of Foremost; and A pre-emptive equity participation right to invest in Foremost's Common Shares to maintain its 19.95% interest. Phase 2: To earn an additional 31% interest in the Exploration Properties, on or before 36 months following the Effective Date, Foremost's obligations include: Paying $2,000,000, in cash or Common Shares or a combination thereof, at the discretion of Foremost to Denison; and Incurring $8,000,000 in exploration expenditures on the Exploration Properties. If the conditions of Phase 2 are not satisfied, Foremost shall forfeit its interests in and rights to the Exploration Properties. Phase 3: To earn an additional 19% interest in the Exploration Properties, on or before 36 months following the successful completion of Phase 2, Foremost's obligations include: Paying $2,500,000, in cash or Common Shares or a combination thereof, at the discretion of Foremost to Denison; and Incurring $12,000,00 in exploration expenditures on the Exploration Properties. If the conditions of Phase 3 are not satisfied, Foremost shall forfeit a portion of its interests in and rights to the Exploration Properties such that Denison's interests in the Exploration Properties will be increased to 51% and operatorship shall revert to Denison. Upon the successful completion of the Option Agreement, the parties would enter into a formal joint venture agreement in respect of the Exploration Properties where the initial ownership interests of Foremost and Denison will be determined based on satisfaction of conditions pursuant to the Option Agreement.

07:09 EDT Tilray unveils portfolio of hemp-derived Delta-9 THC beverages - Tilray Brands, through its newly formed Tilray Alternative Beverages business unit, unveils its portfolio of hemp-derived Delta-9 THC beverages to launch in key markets across the U.S., beginning in October 2024. Tilray's lineup of HDD9 drinks include premium mocktails, seltzers and sparkling drinks made with high-quality hemp extracts and ingredients that provide consumers with a familiar, convenient, and delicious way to relax and unwind.

07:08 EDT Can-Fite BioPharma signs development, commercialization agreement with Vetbiolix - Can-Fite BioPharma announced that its veterinary partner Vetbiolix exercised its option and signed a development and commercialization agreement with Can-Fite for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. Vetbiolix concluded a clinical study in dogs with osteoarthritis who were treated orally with piclidenoson for a couple of months period. The arthritis market for companion animals is estimated by Coherent Market Insights to be $3.8 Billion in 2023 and is expected to grow to $6.3 Billion by 2030. Can-Fite and Vetbiolix model that Piclidenoson has the potential to capture up to 6% of this opportunity, with peak worldwide sales of $445 Million by 2034. Under the agreement, Can-Fite is entitled to receive a 15% royalty on worldwide sales in this indication. This means that Can-Fite's upfront and royalties on sales upon regulatory approval for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2027 launch.

07:07 EDT Vishay to close three manufacturing facilities, reduce workforce - Vishay Intertechnology announced that it is implementing restructuring actions designed to optimize the Company's manufacturing footprint and streamline business decision making as it executes its Vishay 3.0 growth strategy. The restructuring actions will be implemented in phases and include: Selling, general, and administrative functions will be streamlined beginning immediately and through 4Q 2025, resulting in severance payments to approximately 170 employees, or 6% of the SG&A workforce. The closure of three manufacturing facilities. A Diodes segment back-end facility in Shanghai, China is expected to be closed by the end of 2026 with production transfers completed in phases beginning 4Q 2025. In addition, two small facilities in the Resistors segment in Fichtelberg, Germany, and in Milwaukee, Wisconsin, are expected to be closed in 2026. As a result of these facility closures, Vishay will reduce its direct labor by approximately 365 employees, or 2% of its total manufacturing labor workforce. Various changes in manufacturing operations and production transfers, which will result in severance payments to approximately 260 employees. The Company expects to incur pre-tax cash charges of approximately $38 to $42 million, primarily related to severance costs as a result of these programs, mostly in 3Q 2024. Once the program is fully implemented by the end of 2026, Vishay expects to realize annualized cost savings of at least $23 million of which approximately $12 million is expected to be in selling, general and administration expenses. The Company expects to realize immediate annualized cost savings of approximately $9 million. Beginning 1Q 2025, the Company expects to realize approximately $12 million in annualized cost savings.

07:07 EDT Entrada promotes Sethuraman to President of Research, Development - Entrada Therapeutics announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately. Sethuraman joined Entrada Therapeutics as Chief Scientific Officer in 2017

07:06 EDT Acurx announces results of Phase 2 ibezapolstat trial in C. difficile Infection - Acurx Pharmaceuticals announced results from its research with ibezapolstat in collaboration with Leiden University Medical Center. Ibezapolstat is the company's lead antibiotic candidate planning to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection, or CDI. Results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target . Mechanistic findings explain ibezapolstat's properties of lacking cross resistance with other antibiotics and not fostering the emergence of Enterococcus, including vancomycin-resistant strains, a unique differentiation among anti-CDI antibiotics. Acurx previously had a successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for ibezapolstat for treatment of CDI. Agreement with FDA was reached on key elements to move forward with its international Phase 3 clinical trial program and the complete development plan for filing of an NDA for marketing approval. Planning continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of CDI. Acurx is also now preparing to submit requests for regulatory guidance to initiate clinical trials in the EU, the U.K., Japan and Canada. Key elements for the two Phase 3, non-inferiority, pivotal trials were confirmed and included agreement with FDA on the protocol design, patient population, primary and secondary endpoints, and size of the registration safety database. The research outcome is intended to accelerate lead product candidate selection for Acurx's pre-clinical program for other WHO, CDC and FDA high-priority, multi-drug resistant Gram-positive pathogens where new classes of antibiotics are needed.

07:05 EDT Diamondback Energy, Kinetik, EPIC announce transformative transactions - Diamondback Energy (FANG), Kinetik Holdings (KNTK), and EPIC Midstream announced a series of transactions to support the continued growth and strengthened financial profile of EPIC Crude Holdings, an affiliate of EPIC Midstream, including: Diamondback and Kinetik acquired a 30% equity interest in EPIC Crude. The Partners now each own 27.5% of EPIC Crude. EPIC Midstream continues to own a 45% equity interest in and manage the operations of EPIC Crude. Diamondback is converting its existing commitment on EPIC Crude into a significantly larger volume commitment of 200 MBpd to accommodate additional crude barrels from Diamondback's newly completed merger with Endeavor Energy Resources. As a result of that merger, Diamondback is the third largest crude producer in the Permian Basin. Kinetik is also entering into a new transportation arrangement with EPIC Crude and a new connection between Kinetik's crude gathering system and the EPIC Crude pipeline. The combined long-term volume commitments from the Partners are expected to commence in 2025 and extend until 2035, fully supported by minimum volume commitments and representing over 33% of EPIC Crude's volume capacity. EPIC Crude and its Partners are continuing to focus on reducing controllable costs and enhancing financial returns which will further maximize value for all stakeholders of EPIC Crude. Taken together, these actions will position EPIC Crude for long-term success while increasing its long-term strategic alignment with Diamondback and Kinetik.

07:03 EDT PayMate enters binding term sheet for potential DigiAsia acquisition - PayMate India has entered into a binding term sheet for the potential acquisition of DigiAsia Bios, a Fintech-as-a-Service company in Indonesia and a fully owned subsidiary of DigiAsia Corporation. Under the terms of the Proposed Transaction, an enterprise valuation of $400 Million for DigiAsia's business has been determined. Additionally, post the Proposed Transaction, PayMate intends to invest up to $25 Million in cash, the aggregate financing structure and terms will be finalized in mutual agreement. PayMate and DigiAsia will continue joint due diligence on both entities, identification of the right transaction structure, entering into definitive agreements and the necessary corporate and regulatory approvals of PayMate and DigiAsia which is expected to take up to 60 days. Subsequent to the closing of the Proposed Transaction, PayMate intends to initiate proceedings to list the combined entity in India.

06:56 EDT AutoZone opened 68 new stores in the U.S in Q4 - During the quarter ended August 31, 2024, AutoZone opened 68 new stores in the U.S., 31 in Mexico and 18 in Brazil for a total of 117 new stores. For the fiscal year, the Company opened 213 net new stores. As of August 31, 2024, the Company had 6,432 stores in the U.S., 794 in Mexico and 127 in Brazil for a total store count of 7,353.

06:35 EDT GSK's Menveo vaccine receives positive European CHMP opinion - GSK announced that the European Medicine Agency's, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended for use a single-vial, fully liquid presentation of Menveo to help protect against invasive meningococcal disease, IMD, caused by bacterial groups A, C, W, and Y. Marketing authorization in EU expected by November 2024. Over 6 million doses of GSK's MenACWY vaccine have been distributed to European countries since 2017 to help protect against invasive meningococcal disease

06:08 EDT Marriott, Sands China to open Londoner Grand in Macao - Marriott (MAR) and Sands China (SCHYY) are set to debut The Luxury Collection brand to the market. Anticipated to open in January 2025, Londoner Grand, a Luxury Collection Hotel, Macao is poised to cater to travelers.

06:05 EDT KBR awarded $113M Air Force task order - KBR announced it has been awarded an estimated $113M task order to perform aeronautical systems research, development, test and evaluation for the Air Force Life Cycle Management Center Mobility Directorate at Wright-Patterson Air Force Base, Ohio over a period of five years. KBR was awarded this contract under the Department of Defense Information Analysis Center's multiple-award contract vehicle. These IAC MAC task orders are awarded by the U.S. Air Force's 774th Enterprise Sourcing Squadron to develop and create new knowledge for the enhancement of the DTIC repository and the R&D and S&T community. Under the terms of this new contract, KBR will provide program management analysis, engineering, logistics analysis, security and cybersecurity analysis, test and evaluation and administrative analysis. The team will review, update, create and coordinate various program-related products and documents necessary for the development and life cycle management of the Future Tankers Program Office. This work will inform programs such as Next Generation Air-refueling System development and the future recapitalization of legacy tanker aircraft mission systems.

06:03 EDT Eli Lilly announces Japan MHLW approval for Kisunla - The Ministry of Health, Labour and Welfare Japan has approved Kisunla, Eli Lilly's Alzheimer's treatment for adults with early symptomatic Alzheimer's disease, or AD, which includes people with mild cognitive impairment as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.

05:53 EDT Generations Bancorp NY to delist stock from Nasdaq - Generations Bancorp NY announced its voluntary decision to delist its common stock from Nasdaq and its intent to deregister its common stock with the SEC. The company has notified Nasdaq of its intent to voluntarily delist and withdraw the registration of its common stock with the SEC. The company intends to file a Form 25 with the SEC on October 4 and expects the last trading day of the company's common stock on Nasdaq will be on October 4. Following delisting from Nasdaq, the company expects its common stock will be quoted on the OTCQX Market beginning on October 7.

05:40 EDT UCB, Biogen announce topline results from PHOENYCS GO study - UCB and Biogen announced topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe systemic lupus erythematosus, or SLE. Dapirolizumab pegol, in addition to standard-of-care, or SOC, treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group, or BILAG-based Composite Lupus Assessment, or BICLA, after 48 weeks versus placebo in addition to SOC. Clinical improvements were observed among key secondary endpoints measuring disease activity and flares. The safety profile of dapirolizumab pegol was generally consistent with previous studies and with that expected in study participants with systemic lupus erythematosus receiving an immunomodulator. Based on the successful outcome of the PHOENYCS GO study, UCB and Biogen are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY. Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study. PHOENYCS GO is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of dapirolizumab pegol as an add on therapy to standard of care compared to placebo with standard of care. The primary outcome measure was improvement of moderate-to-severe disease activity at Week 48 using BICLA, an established, composite primary efficacy endpoint for measurement of clinical disease activity based on patient medical history, clinical examination and laboratory tests. Detailed results from the PHOENYCS GO study will be presented at an upcoming medical congress.

05:34 EDT Astellas Pharma announces Japan MHLW approval of Padcev with Keytruda - Astellas Pharma (ALPMY) announced that Japan's Ministry of Health, Labour and Welfare, or MHLW, has approved Padcev with Merck's (MRK) Keytruda as a combination therapy for the first-line treatment of adult patients with radically unresectable urothelial carcinoma. This is the first approved combination treatment for radically unresectable urothelial cancer in Japan to offer an alternative to platinum-containing chemotherapy, the current standard of care for first-line treatment.

05:28 EDT Nokia selected by Spark New Zealand to expand 4G, 5G program in New Zealand - Nokia announced that it has been selected by Spark New Zealand to expand its existing 4G and 5G program in cities across New Zealand. Spark has chosen Nokia as its preferred 5G Radio Access Network partner to streamline operations and consolidate its RAN. This strategic decision will simplify network operations while delivering the 5G network in New Zealand. Under the deal, covering over 700 sites, Nokia will provide equipment from its 5G AirScale portfolio. This includes baseband, remote radio heads, and massive MIMO radios, offering 5G capacity, coverage, and connectivity. These solutions utilize Nokia's energy-efficient ReefShark System-on-Chip technology, delivering superior capacity and connectivity to Spark customers while reducing complexity and improving cost efficiencies.

05:23 EDT UL Solutions announces certification on Europe of Alpitronic fast EV charger - UL Solutions announced its first certification in Europe of a fast EV charger made by Alpitronic. The Alpitronic HYC400 is the first 400-kilowatt system to achieve UL certification from UL Solutions in Europe to UL 2202, the Standard for DC Charging Equipment for Electric Vehicles, a U.S. scheme, that marks Alpitronic's formal entry into the North American market.

05:16 EDT Corpay named official foreign exchange supplier of Everton FC - Corpay announced that Corpay's cross-border business has entered into an agreement with Everton FC, one of the founding members of the Premier League to become their official foreign exchange supplier. Through this partnership, Everton will be able to utilize Corpay Cross Border's solutions to help mitigate foreign exchange exposure from their day-to-day business needs.